Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 7,489 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $320,678.98. Following the transaction, the chief executive officer now directly owns 119,359 shares in the company, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Mirum Pharmaceuticals Stock Down 0.1 %

Shares of MIRM opened at $42.00 on Thursday. The company has a market capitalization of $2.02 billion, a P/E ratio of -20.79 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $48.89. The business’s 50 day simple moving average is $42.86 and its 200-day simple moving average is $40.61. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. During the same quarter in the prior year, the business earned ($0.57) earnings per share. The business’s revenue for the quarter was up 89.4% on a year-over-year basis. As a group, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quest Partners LLC increased its stake in shares of Mirum Pharmaceuticals by 7,513.3% in the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after buying an additional 1,127 shares during the period. Amalgamated Bank boosted its stake in Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after acquiring an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $215,000. Finally, ProShare Advisors LLC bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth $213,000.

Wall Street Analyst Weigh In

MIRM has been the subject of several analyst reports. Leerink Partners lifted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Citigroup increased their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Buy” and an average price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.